Technical analysis of Royalty Pharma plc (RPRX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Price Performance
| 1 month | +17.53% |
| 3 months | +17.51% |
| Year-to-date | +73.86% |
| 1 year | +78.96% |
| 3 years | +144.47% |
| 5 years | +76.28% |
52-Week Range
| 52-week High | $67.70 |
| 52-week Low | $36.03 |
| Avg Volume (90d) | 3.0M |
Technical Indicators
| SMA 50 | $60.28 |
| SMA 200 | $53.22 |
| Beta | 0.39 |
| 30-day Volatility (annualised) | 22.7% |
| Price vs SMA 50 | +11.5% |
| Price vs SMA 200 | +26.2% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $38.64 | |
| 2026-01 | $41.68 | +7.9% |
| 2026-02 | $46.21 | +10.9% |
| 2026-03 | $47.97 | +3.8% |
| 2026-04 | $50.09 | +4.4% |
| 2026-05 | $55.76 | +11.3% |
| 2026-06 | $56.07 | +0.6% |
| 2026-07 | $58.43 | +4.2% |
| 2026-08 | $61.41 | +5.1% |
| 2026-09 | $58.36 | -5.0% |
| 2026-10 | $67.18 | +15.1% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-04 | $1.18 | $885M |
| 2026-08-05 | $1.27 | $759M |
| 2026-05-06 | $1.21 | $882M |
| 2026-02-11 | $1.29 | $807M |
| 2025-11-05 | $0.99 | $717M |
| 2025-08-06 | $1.03 | $673M |
| 2025-05-08 | $0.95 | $705M |
Price
| Price | $67.18 (closing price, October 30, 2026) |
| Market Cap | $29.9B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 38.61 |
| Price / Book | 4.38 |
| EV / EBITDA | 22.18 |
| Dividend Yield | 1.38% |
Financial Health
| Debt / Equity | 1.31 |
| Current Ratio | 1.29 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 1.56 |